Development of class III antiarrhythmic agents.
Currently available antiarrhythmic agents that act by lengthening the action potential duration and refractory period exert most of their effect during bradycardia (class IIIB). Unfortunately, when these agents are most needed, i.e., during tachycardia, they lose most of their effect. In my opinion, ideally, antiarrhythmic agents need not change the electrophysiology of the normal sinus beat, but should lengthen refractoriness upon acceleration (class IIIA) of the heart until the refractory period exceeds the cycle length of the tachycardia. Three examples of how such class IIIA effects can be achieved are: (i) an upstroke-dependent activator of inward currents could form a universal class IIIA agent, (ii) a use-dependent blocker of iTO could be a great class IIIA agent in the atria, and (iii) a frequency-dependent blocker of late repolarizing currents (e.g., iKs) could be a good target for a ventricular agent.
D000889:Anti-Arrhythmia Agents / Q000145:classification / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D011955:Receptors, Drug / Q000378:metabolism; D012449:Safety
D000889:Anti-Arrhythmia Agents; D011955:Receptors, Drug